Sales grew 8.2% y/y to PLN 13.64 bn with stable profitability, while net profit rose 0.9% to PLN 155.6 m. Medical and insurance segments delivered double-digit revenue growth, and dividends reached PLN 16/share. Negative FX and clinical trial project cancellations impacted results.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.